What question did this study set out to answer?

The aim is to evaluate the STRATOS-P clinical model's effectiveness in predicting overall survival and selecting patients for intermittent therapy in metastatic hormone sensitive prostate cancer.

May 29, 2026

STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.

Key Points

The aim is to evaluate the STRATOS-P clinical model's effectiveness in predicting overall survival and selecting patients for intermittent therapy in metastatic hormone sensitive prostate cancer.
Retrospective study of veterans diagnosed with metastatic hormone sensitive prostate cancer (N=3094) from 2018-2024.
Utilized PSA response and genomic assessments to stratify risk using the STRATOS-P model.
Analyses included Kaplan-Meier for overall survival estimates and multivariable Cox models for risk assessment.
Of 937 patients with genomic testing, median overall survival for low risk was not reached, vs 37.1 months for moderate risk and 19.1 months for high risk (p<0.001).
Approximately 497 patients (53%) eligible for intermittent therapy had a median overall survival of 77.9 months, similar to those with PSA ≤0.2 ng/mL.
Higher genomic risk scores correlated with worse overall survival and progression-free survival outcomes.

Abstract

5106 Background: Current trials use prostate-specific antigen (PSA) response of ≤0.2 ng/mL at 6-12 months as a prognostic marker and identify patients for intermittent therapy. Clinico-genomic assessment can increase prognostic accuracy and patient selection for intermittent therapy, which would improve quality of life and decrease adverse events associated with mHSPC combination therapies without impacting survival. Methods: Retrospective study of veterans diagnosed with mHSPC between 2018-2024. PSA response at 6-12 months and volume of disease were determined. DNA alterations were classified by Somatic Tumor Risk Assessment for Overall Survival-Prostate (STRATOS-P) genomic system, a validated method of risk stratification. PSA response was grouped into ≤0.2, >0.2-0.2 - 2 210 1.60 1.25-2.04 PSA Response# >2 - <10 131 2.98 2.30-3.84 10+ 87 5.64 4.26-7.47 *STRATOS-P genomic risk favorable is referent, n=335. #PSA Response ≤0.2 is referent, n=509.

AI से पूछें

Bookmark

Cite This Study

Schoen et al. (Wed,) studied this question.

synapsesocial.com/papers/6a192f2dfab5b468c44189b0 https://doi.org/https://doi.org/10.1200/jco.2026.44.16_suppl.5106

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI से पूछें

Bookmark